Abstract: Selenium is an essential micronutrient that is required for the synthesis of selenocysteine-containing selenoproteins, processing a wide range of health effects. It is known that the thyroid is one of the tissues that contain more selenium. The “selenostasis” maintenance seems to contribute to the prevention of immune mediated thyroid disorders. Prospective, observational studies, randomized, controlled studies evaluating selenium supplementation, and review articles that are available in Medline and PubMed have undergone scrutiny. The differences concerning methodology and results variability have been analyzed. Several authors support the idea of a potential efficacy of selenium (mainly selenomethionine) supplementation in reducing antithyroperoxidase antibody levels and improve thyroid ultrasound features. In mild Graves’ orbitopathy, selenium supplementation has been associated with a decrease of the activity, as well as with quality of life improvement. Future research is necessary to clearly understand the selenium supplementation biologic effects while considering the basal selenium levels/biomarkers, selenoprotein gene polymorphisms that may be involved, underlying comorbidities and the major clinical outcomes.

Keywords: selenium; selenoproteins; essential trace element; supplements; autoimmune thyroid diseases; Hashimoto’s thyroiditis; Graves’ disease

1. Introduction

Normal thyroid function depends on many elements that are necessary for the synthesis and metabolism of thyroid hormones [1]. Selenium (Se) is an essential trace element (atomic number 34), discovered by the Swedish chemist Jons Jacob Berzelius in 1817 [2]. He named the new element “σελήνη—Selene” the goddess of the moon in ancient Greece. After 200 years of its first description, the role and the relevance of Se in human health start to be recognized [3]. In the past, Se was even considered a carcinogen, and now it is recognized as a vital nutrient. Schwarz and Foltz have contributed to the change on the conception of selenium. Schwarz was interested in understanding the liver necrosis that is found in laboratory rats when feeding on a diet containing torula yeast. After changing torula yeast to Saccharomyces yeast, the problem disappeared. Through this experience, Schwarz was able to show that torula was deficient in selenium and identified the first selenium-responsive disease [4]. The thyroid gland, in particular, is characterized by a high
concentration of selenium, which is incorporated in several selenoproteins with key functions in the gland [5]. Not surprising selenium deficiency may impair thyroid function. In the scientific community, Se is considered as a topic of increasing interest. In this article, we will summarize the interactions between selenium, selenoproteins and the immune mediated disorders of the thyroid gland.

1.1. Selenium Intake, Biotransformation and Toxicity

Selenium is present in environment in organic compounds (selenomethionine and selenocysteine) and in inorganic compounds (selenite and selenate) [5]. Selenomethionine is found in vegetable sources and selenium yeast. The inorganic forms are present in the soils and are the main components of dietary supplements [6]. Dietary Se is essential in trace amounts and it is obtained through a wide variety of food sources, including grains, vegetables, seafood, meat, dairy products, and nuts [7]. A Belgian study states that the main sources of selenium are meat products (31%), fish (19%), pasta or rice (12%), and bread or cereals (11%) [8]. Most of the selenium is absorbed in the small intestine (50–80%). Selenium is mainly excreted by the kidneys (60%), followed by intestine (35%), and only 5% is excreted in sweat or saliva [9].

It is estimated that about 15% of the world population suffers from Se deficiency and the intake of selenium varies extremely worldwide. In Europe, dietary selenium intake is around 40 µg per day. In the United States of America (USA) the dietary selenium intake ranges from 93 µg per day in women to 134 µg per day in men [10]. Regarding gender, in the UK, the recommended daily selenium allowance is 75 µg/day for men and 60 µg/day for women [9]. The reasons for the world variability in intake include not only the selenium content in the soil, but also factors that determine the availability of selenium to the food chain (selenium type, soil pH, organic matter content, and ions) [11]. For example, selenium content in most parts of Europe is lower than in the United States and in average the selenium intake in Eastern Europe is lower than in Western Europe. For instance, in Finland the selenium content of the soil is extremely low, which resulted in a high incidence of selenium deficiency diseases. In order to increase the Se intake, the Ministry of Agriculture and Forestry in 1984, introduced a multinutrient fertilizer with sodium selenate. The plasma Se concentrations in healthy Finnish adults have been monitored regularly. In the 70s, the low dietary intake of Se, 25 µg/day was reflected in a plasma Se level of 0.63–0.76 µmol/L, which was among the lowest values that were reported in the world. With the supplementation of fertilizers with Se, the plasma selenium concentrations have increased by 70 percent, a level that is above the general plasma Se value in Europe, but is lower than that found in Canada or USA [12].

On the other hand, in the Amazonas region, there is a high Se intake. It is known that Brazil nuts (from the Brazil nut tree—Bertholletia excelsa) are the richest food source of selenium. In 2017, Silva Junior and collaborators verified that the median Se concentration in Brazil nuts ranged from 2.07 mg·kg\(^{-1}\) (in Mato Grosso state, Brazil) to 68.15 mg·kg\(^{-1}\) (in Amazonas state, Brazil). When the soils were analyzed the highest Se concentrations were observed in soil samples from the state of Amazonas. Therefore, Se accumulation in Brazil nuts is increased in soils with higher Se content [13].

China has areas of selenium deficiency affecting up to 105 million of people and areas where it is reported cases of Se excess [14]. Overt Se deficiency results in a condition called Keshan Disease (KD), which is an endemic cardiomyopathy occurring in low selenium areas of China. KD results in heart failure, cardiac enlargement, arrhythmias, and premature death. This condition has been associated with Se intake of 20 µg/day or less and it is known to be responsive to sodium selenite supplementation, although some authors consider that KD cannot be explained solely on low selenium status [15]. When describing selenium excess, Selenosis (a condition that can arise when selenium concentration exceeds 400 µg per day) should be also considered. Se toxicity symptoms are garlic breath, hair and nail loss, disorders of the nervous system, including paralysis, skin diseases, and poor dental health [11], and it was first described in parts of the population of the Hubei Province of the People’s Republic of China. Remounting from 1961 to 1964, the morbidity was almost 50% and its cause was determined to be due to selenium intoxication [16]. Nowadays, extreme toxicity of Se
is not commonly found in humans. Miscalculated supplement formulations, accidental overdose, or intentional poisoning [17] have been reported, as is the case of 201 people that were affected by acute selenium toxicity associated with a misformulated supplement of sodium selenite. After the supplement suspension, the urine selenium concentration returned to normality in weeks [18].

Concerning the secondary effects of excessive selenium intake, in one of the few long-term studies, which included 1202 individuals, the authors found an increased risk of diabetes (hazard ratio 2.7) in patients taking selenium at 200 \( \mu \text{g/day} \). These results should be taken with caution, since the diagnosis of diabetes was self-reported. Additionally, the study took place in an area with high basal selenium content [19].

1.2. Selenium and Selenoproteins

Selenium is inserted as selenocysteine (Sec). The biological effects of Se are mainly exerted through its incorporation into selenoproteins [20]. Dietary Se is incorporated within a complex selenoprotein biosynthesis pathway (Figure 1) present in all cell types. In humans, there are 25 identified genes encoding selenoproteins [21]. Mice lacking Sec tRNA\[^{[\text{SerSec}]}\] gene, required for the translation of selenoproteins, were embryonic lethal demonstrating that selenoprotein expression is essential for life [22]. Alterations in the expression of tRNA\[^{[\text{SerSec}]}\] results in changes on the expression of selenoproteins. Two different Sec tRNAs, that differ only on a single methylated base occurring on the 2’-O-hydroxyribsylo moiety at position 34 are expressed in different subclasses of selenoproteins, namely the housekeeping and the stress-related selenoproteins. Recently, Carlson et al. demonstrated new methods for the isolation and sequencing of selenocysteines tRNA [23], opening new windows for the study of selenoproteins proteasome.

![Figure 1](image-url). Selenoprotein biosynthesis pathway that is initiated by the charging of serine (Ser) onto a tRNA (tRNA Sec) in order to generate a Ser-tRNA Sec. The seryl-tRNA residue of Ser-tRNA Sec is then phosphorylated and converted to selenocysteyl-tRNA (Sec-tRNA sec). The Sec tRNA is used as Sec transfer into selenoproteins through the action of cis elements present in the selenoprotein mRNA and protein factors including SECIS binding protein 2 (SBO2) and Sec specific translational elongation factor (EF sec).
1.3. Selenium and Thyroid Gland

The thyroid gland is characterized by a high concentration of selenium, and it is known that selenium and selenoproteins play an important role in thyroid function. In support of this hypothesis, low selenium levels have been found in the African area of Zaire where myxoedema is endemic, suggesting a role of this oligoelement. In 1987, Goyens and collaborators described myxoedematous endemic cretinism as a thyroid exhaustion atrophy [24]. In order to understand clearly the role of selenium, in a group of schoolchildren in the Northern Zaire with known deficiency of selenium and iodine, selenium supplementation resulted in a decrease in serum thyroxine and reverse triiodothyronine concentrations [25]. Since then, research on the implications of selenium on thyroid physiopathology was conducted. Most of the known selenoproteins are expressed in the thyroid gland (Table 1 and Figure 2). In 1973, glutathione peroxidase was the first selenoprotein characterized [26]. At the same time, it was documented the presence of two different enzymes that catalyze the conversion of thyroxine (T4) to triiodothyronine (T3): iodothyronine deiodinase type 1 and 2 (DOI 1 and 2). Later on, in 1991, it was proved that selenium was incorporated into iodothyronine deiodinases 1 (DOI 1) [27]. Therefore, selenium deficiency leads to a reduction on the expression and activity of these enzymes, which results in an increase on T4 and a decrease on T3 levels. In accordance, experiments in rodents that have been fed with a low selenium diet showed increase in T4 levels and decrease in T3 levels [28]. Recently, Kawai and collaborators verified that children with severe selenium deficiency had high free T4 levels that were reduced with Se supplementation [29]. Among other well characterized selenoproteins, are the enzymes that are involved in the regulation of redox state and protection from oxidative damage, the thioredoxin reductases.

Table 1. Selenoproteins expressed in the thyroid and/or involved in the biosynthesis of thyroid hormone and protection of the thyroid gland (adapted from [5,14,20]).

| Selenoproteins          | Abbreviations | Function                                               |
|-------------------------|---------------|--------------------------------------------------------|
| Glutathione Peroxidase | Gpx           | Catalyzes \( \text{H}_2\text{O}_2 \) reduction; Protects against oxidative stress |
| Cytosolic GPx1           | cGPx1         | Antioxidative defense; Type of reserve                 |
| Extracellular GPx        | pGPx 3        | Anti-inflammatory action                               |
| Phospholipid GPx         | GPx4          | Decreases phospholipid hydroperoxidases, moderates apoptosis |
| Iodothyronine deiodinase | DIO           | Conversion of active thyroid hormone T3, reverse T3 and T2 |
| Type I DI                | DI-I          | Conversion of T4 to T3                                 |
| Type II DI               | DI-II         | Local production (intracellular) of T3 from T4         |
| Type III DI              | DI-III        | Conversion of reverse T3 from T4 and T2 from T3        |
| Thioredoxin reductase    | TXNRD         | Oxidoreductase activity having NADPH as a cofactor     |
| Cytosolic TRx-1          | TRx1          | Regulates cellular redox level, cell development and proliferation |
| Mitochondrial TRx        | TRx2          | Regulates cell proliferation, tissue development       |
| Various                  |               |-------------|--------------------------------------------------------|
| Selenoprotein P           | SELENOP       | Selenium transport, antioxidant defense                |
| Selenoprotein N           | SELENON       | Degradation \( \text{H}_2\text{O}_2 \)                |
| Selenoprotein S           | SELENOS       | Quality control within the endoplasmic reticulum     |
| Selenoprotein K           | SELENOK       | Quality control within the endoplasmic reticulum     |
| Methionine sulfoxide reductase B1 | MSRB1    | Oxidative stress protection                           |

The table shows different selenoproteins with known thyroid-related functions. T4—thyroxine; T3—triiodothyronine; T2—3,5-diiodo-L-thyronine; \( \text{H}_2\text{O}_2 \)—Hydrogen peroxide.
Figure 2. Examples of selenoproteins present in thyrocytes include SELENOP and glutathione peroxidase 3 (GPx3) that are actively secreted. SELENOS and SELENOK that have a role in quality control pathways within the endoplasmic reticulum (ER). Type 1 and 2 iodothyronine deiodinases (DIO1, DIO2), GPx1 and GPx4, methionine sulfoxide reductase B1 (MSRB1), selenophosphate synthetase 2 (SPS2), and thioredoxin reductase 1 (TXNRD1) are intracellular selenoenzymes. TXNRD2 and a GPx4 isozyme are localized in mitochondria. SBP2, which is a factor responsible for the selenoprotein translocation control.

Biosynthesis of selenoproteins can be affected by germline mutations. SECISBP2 gene encodes one of the essential components involved in co-translational insertion of selenocysteine (Sec) into selenoproteins. Mutation of SECISBP2 is associated with a multisystem disorder and is reported by Schoenmakers and collaborators [30] when considering that the phenotype reflects tissue-specific effects caused by particular selenoprotein deficiencies and generalized antioxidant selenoenzyme deficiencies with excess cellular ROS [30]. Recently, it was proposed that patients with SECISBP2 and TRU-TCA1-1 defects manifest a multisystem disorder with a biochemical signature of abnormal thyroid function tests due to the impaired activity of deiodinase selenoenzymes, myopathy features that are linked to SEPN1 deficiency and phenotypes resulting from increased levels of reactive oxygen species attributable to lack of antioxidant selenoenzymes [31]. Dumitrescu and collaborators reported an inherited defect that was caused by a homozygous missense mutation of SECISBP2 that disrupts thyroid hormone metabolism [32]. Another report detailed the SECISBP2 gene mutation, R128X, which creates a premature stop codon in the molecule [33]. Recently, sequencing of DNA revealed a novel SECISBP2 mutation in a Turkish boy that presented high T4, low T3, high rT3, and normal or slightly elevated TSH [34].

1.4. Selenium and Immune Mediated Thyroid Disorders

Graves’ disease (GD) and Hashimoto thyroiditis (HT) are the most common forms of autoimmune thyroid diseases (AITD). AITD affects more than 1–2% of the world population and it is diagnosed mostly in women between 30–50 years of age [35]. Graves’ disease is about one-tenth as common as HT and it tends to occur in younger individuals. Overall, a third of GD patients develop ophthalmic signs of Graves’ disease.
AITD pathogenesis is not yet clarified, but common and unique susceptibility genes have been proposed [36] in recent genome-wide association studies [37]. Recently, it was suggested that selenoproteins amount and activity are related to single nucleotide polymorphisms (SNPs) in selenoprotein genes, which can interfere with disease risk. Previous work that was published by our group suggested that there is a link between SELENOS (SEPS1) promoter genetic variation and Hashimoto’s thyroiditis (HT) risk. A total of 997 individuals comprising 481 HT patients and 516 unrelated controls were enrolled in the study. We found that individuals with SELENOS-105 GA and AA genotypes have a higher risk to develop HT (odds ratio (OR) 2.24, confidence interval (CI) 1.67–3.02, \( p < 5.0 \times 10^{-7} \), versus, OR 2.08, CI 1.09–3.97, \( p = 0.0268 \), genotype, respectively) [38]; sexual dimorphism was also found in SELENOS-105GA genotypes distribution. Recently, Seale and collaborators highlighted the importance of considering sex differences in selenoproteins metabolism, expression, and action, which can be, in part, explained by endocrinological differences [39].

Reduced serum selenium concentrations (below 70 \( \mu g/L \)) are reported in patients with autoimmune thyroid disorders [40]. Several studies were undertaken in patients with AITD, especially in areas with low to borderline selenium content, aiming at understanding whether supplementation may have an impact on the evolution of thyroid immune mediated disease. The majority of the studies suggest that Se supplementation may decrease circulating thyroid autoantibodies, but the trials until now were heterogeneous in terms of number of patients, different forms of selenium supplements, duration of the supplementation, evaluation of thyroid by ultrasound, and serum selenium measurement. In Table 2, we presented a summary of the general characteristics and outcomes of selenium supplementation studies in patients with Hashimoto’s thyroiditis. Two groups were formed according to the type of supplement used (sodium selenite versus selenomethionine) and divided by doses or duration of treatment. In Table 2 is also shown whether the studies measured selenium levels at beginning or if the ultrasound features are checked during the trial.

Selenium supplementation in patients with AITD seems to modify the inflammatory and immune responses. The main proposed mechanisms include enhancing plasma GPX and TR activity and decreasing the toxic concentrations of hydrogen peroxide (H\(_2\)O\(_2\)) and lipid hydroperoxides [41,42].

Table 2. Summary of studies of selenium supplementation in patients with Hashimoto’s thyroiditis and corresponding outcomes.

| Sample Size (F/M) | Supplementation Regimen | Duration of Treatment | Level of Se | TPOab Levels | Ultrasound Evaluation | Country | Reference |
|------------------|-------------------------|----------------------|-------------|--------------|----------------------|---------|-----------|
| 71 (71/9)        | 200 \( \mu g \) NaSeO\(_3\) per day | 90 days               | √                        | Decreased by 36% | √                     | Germany | Gardner 2002 [43] |
| 36 (36/9)        | 200 \( \mu g \) NaSeO\(_3\) per day | 90 days               | ×                        | No effect     | ×                     | Austria | Karanikas 2008 [44] |
| 70 (45/25)       | 200 \( \mu g \) NaSeO\(_3\) per day | 3 months              | √                        | No effect     | ×                     | Iran    | Kachouei 2018 [45]  |
| 61 (NA)          | 200 \( \mu g \) NaSeO\(_3\) per day | 6 months              | √                        | No effect     | √                     | The Netherlands | Eskes 2014 [46] |
| 88 (88/0)        | 200 \( \mu g \) SeMet per day     | 3 months              | ×                        | Decreased by 26% | ×                     | Turkey  | Turkoglu 2006 [47]  |
| 86 (53/33)       | 200 \( \mu g \) SeMet per day     | 3 and 6 months        | √                        | Decreased TgAb | √                     | Greece  | Anastasiakakis 2012 [48] |
| 55 (50/5)        | 200 \( \mu g \) SeMet per day     | 3 months and 6 months | √                        | Decreased by 5% | (3 m.) and 20% (6 m.) | Brazil | De Farias 2015 [49] |
| 65 (56/9)        | 200 \( \mu g \) SeMet per day     | 6 months              | √                        | Decreased by 56% | ×                     | Greece  | Duntas 2003 [50]  |
| 80 (80/0)        | 200 \( \mu g \) SeMet per day     | 6 months + 6 months   | ×                        | Decreased by 21% | ×                     | Greece  | Mazokopakis 2007 [51] |
| 76 (76/0)        | 166 \( \mu g \) SeMet per day     | 6 months              | ×                        | No effect     | √                     | Italy   | Esposito 2016 [52] |
| 88 (88/0)        | 100 \( \mu g \) SeMet per day     | 3 months              | ×                        | No effect     | ×                     | Turkey  | Turkoglu 2006 [47]  |
| 76 (65/11)       | 80 \( \mu g \) SeMet per day      | 6 months and 1 year   | ×                        | Decreased after 12 m. | √                     | Italy   | Nacamulli 2010 [53] |
| 60 (60/0)        | 80 \( \mu g \) SeMet vs. 160 \( \mu g \) SeMet per day | 1 year               | ×                        | No effect     | √                     | Italy   | Pilli 2015 [54]  |
| 253 (NA)         | 100 \( \mu g \) yeast derived Se | 1 year                | ×                        | No effect     | ×                     | Czech Republic | Kvicica 2009 [55] |

F, female; M, male; NA, not available; NaSeO\(_3\), sodium selenite; SeMet selenomethionine; TPOab; thyroid peroxidase antibody; × not done; √ evaluated.
Since 2002, several trials have investigated the effect of selenium supplementation. The first placebo-controlled clinical study with selenium in AITD was conducted in Bavaria/Germany, an area with known selenium deficiency. In this study, the effect of supplementing diet with 200 µg sodium selenite per day for 90 days was evaluated. Patients were divided into two groups: one group that was supplemented with sodium selenite and the other group that kept therapy with levothyroxine. At the end of the study, the concentration of anti-TPO antibodies decreased by 36% in the group that was treated with selenium (versus 10% in the placebo group). During this period, in 9 out of 36 patients (25%) anti-TPO level was completely normalized and thyroid echogenicity also improved [43]. In an extension of Gartner study, one group of patients continued taking sodium selenite, which increased the reduction of anti-TPO to 43%, whereas the group that originally had received placebo was put on selenium and reached a reduction of 45% in anti-TPO antibodies levels [56].

Duntas and collaborators conducted a randomized, placebo-controlled trial, in which 65 patients with AITD were included [50]. In the group that were supplemented with selenomethionine, the level of TPOab decreased 46% after three months and 55.5% after six months, when compared to a decrease of only 21% and 27%, respectively, at three and six months in the group under isolated therapy with thyroxine [50].

Another study evaluated the effects of long-term (9 months) supplementation with variable doses of selenomethionine (100/200 µg per day) on autoimmune thyroiditis, particularly on the concentration of TPOab and TgAb. A total of 88 women with AITD, under thyroxine treatment were included in the study. The group supplemented during the nine months with 200 µg/day selenomethionine had a decrease in serum levels of TPOab until six months of treatment (26.6% at three months, 26.2% at six months) at nine months there was a decrease of only 3.6% in serum levels of TPOab. The authors proposed that doses of l-selenomethionine higher than 100 µg per day are necessary to suppress serum concentrations of TPOab in patients with AITD and to maximize glutathione peroxidase activities [47].

Nacamulli and collaborators, verified that supplementation with physiological doses of selenium (80 µg/day of sodium selenite) for 12 months reduces the echogenicity of the thyroid and TPOab and TgAb levels, but it does not modify TSH or FT4 [53].

Supplementation of Czech seniors with selenium rich yeast extract did not reduce TPO autoantibody concentrations [55]. Similarly, sodium selenite supplementation of Dutch patients with HT had no effect on TPO autoantibody concentrations, although serum selenium status did increase [46]. One study indicated that high (200 µg/day) but not moderate (100 µg/day) dosage is required to have a positive effect of supplementation. A low dose (80 µg/day) proved effective in another trial. No adverse effects were noted in these trials, and therefore, routine selenium supplementation in patients with Hashimoto thyroiditis has been discussed as a promising adjuvant treatment option [46].

Ferrari and collaborators recently published the beneficial effects of myo-inositol in association with selenomethionine in 21 patients [57]. The authors first showed an immune modulatory effect of myo-inositol in association with selenomethionine in patients with euthyroid AITD. After treatment, TSH levels significantly declined suggesting that the combined treatment can reduce the risk of progression to hypothyroidism in subjects with AITD [57].

Taking together the information collected in recently published systematic reviews, clinical trials, and meta-analysis, Se supplementation effectively reduces serum TPOab levels at 3, 6, and 12 months and serum TgAb at 12 months in LT4-treated populations. However, in LT4-treated patients, no significant correlation between the baseline serum Se and the decrease in serum TPOab level was demonstrated [58]. This meta-analysis also indicates that the formulation used is relevant, since a significant decrease in serum TPOab levels was seen in groups of patients receiving 200 µg selenomethionine, but not in those receiving 200 µg sodium selenite [58]. This can be related with the differential absorption of selenite that is approximately two-thirds of the absorption of selenomethionine. Still, in an additional meta-analysis present in the Cochrane library, the authors concluded that the available data is insufficient to support or refute the efficacy of Se supplementation in patients with HT [59]. It is important to note that, in most of the studies that focus on the
relevance of selenium to thyroid disease, the authors did not measure selenium concentration prior to, during, and after supplementation. Furthermore, the most frequent primary outcome measurement was thyroid antibodies levels, so, at the present time, there is no recommendation for selenium supplementation in patients with AITD. The results to be obtained in an ongoing randomized controlled trial, the CATALYST trial (“The chronic autoimmune thyroiditis quality of life selenium trial”) that enrolled 472 patients with autoimmune thyroiditis treated with LT4, will be very important to settle the controversy. The primary aim of the trial is to study the effect of 12 months 200 µg selenium-enriched yeast supplementation versus placebo on thyroid-related quality of life. In this trial, at variance with other studies about this issue, plasma selenium concentrations will be measured periodically to assess selenium intake [60].

Postpartum Thyroiditis (PPT) is the most common and the most well characterized cause of thyroid dysfunctions in the postpartum period. Selenium supplementation has been suggested as a potential approach to the prevention and treatment of PPT. In Al-Kunani and collaborators’ study [61], women who suffered spontaneous abortion had lower selenium capillary levels than the group which had achieved term gestation and in the study by Negro and collaborators [62], supplementation of selenium was associated with significant reduction in anti-TPO antibody titer and significant improvement of the ultrasound thyroiditis pattern in pregnant women with autoimmune thyroiditis. This was accompanied by a significant reduction in the incidence of postpartum thyroid dysfunction and permanent hypothyroidism.

1.5. Selenium and Graves’ Disease

Several groups have analyzed the importance of selenium supplementation in patients with Graves’ disease. One of the first studies published in Graves’ disease evaluated the supplementation effect of a combination of antioxidants in a group of patients with Graves’ disease treated with methimazole. Patients who received supplementation with antioxidants in addition to therapy with methimazole attained more rapid biochemical and clinical remission than those who receive methimazole alone [63]. Wang and collaborators enrolled 41 patients with recurrent Graves’ disease who were under treatment with methimazole [64]. For six months, 21 patients were supplemented with sodium selenite (200 µg/day) in addition to methimazole vs. 20 patients without supplementation. The authors found a decreased of both, FT4 and FT3 at two months, in the selenium group when compared with the control group. A significantly lower level of TRAbs was detected in patients receiving selenium supplementation (2.4 IU/L vs. 5.6 IU/L, \(p = 0.04\)). At six months, a significantly higher percentage of patients with lower TRAbs levels was detected in the selenium group (19.0% vs. 0%, \(p = 0.016\)). These results suggest that selenium supplementation can enhance the effect of antithyroid drugs in patients with recurrent Graves’ disease (GD) [64].

The retrospective study performed by Wertenbruch in 2007 is pertinent [65]. The authors analyzed 83 patients with GD in an active form. Of that, 24 GD patients went into remission and the mean levels of anti-TSH antibodies (TRAbs levels) were significantly lower than in the relapse group (2.1 as compared to 8.6 IU/L; \(p < 0.0001\)). When remission and relapse group were compared, the serum Se levels in the remission group were higher (73.0 vs. 71.7 µg/L). The highest serum Se levels (> 120 µg/L) were seen in the remission group, suggesting a role of Se levels in GD outcome [65]. At variance, Leo and collaborators found no effect of 166 µg/day adjuvant selenomethionine for three months in 30 Graves’ disease patients [66].

Graves’ orbitopathy (GO) is a major manifestation of autoimmune hyperthyroidism, which commonly affects patients with Graves’ disease. Marcocci and collaborators carried out a randomized, double-blind, placebo-controlled trial to determine the effect of selenium or pentoxifylline in 152 patients with mild Graves’ orbitopathy [67]. They found that treatment with selenium, but not with pentoxifylline, was associated with improved quality of life, less eye involvement, and delayed progression of Graves’ orbitopathy at six months. The patients were subsequently reassessed at 12 months (after 6 months without selenium, pentoxifylline, or placebo supplementation), and the
results obtained in the first assessment were confirmed [67]. Although the evidence concerning selenium benefits in GO comes from this single randomized controlled study, a recommendation for its use in GO mild cases was incorporated into the recent guidelines from the European Group On Graves’ Orbitopathy (EUGOGO) [68].

In an Australian study incorporating around 200 patients, the authors reported significantly lower mean serum Se levels in patients with GO (1.10 ± 0.18 µm) when compared to GD patients without GO (1.19 ± 0.20 µm) (p = 0.001) [58]. In Dehina and collaborators’ study [69], serum Se and selenoprotein P (SELENOP) concentrations were determined in 84 consecutive patients with GO before treatment and compared to their clinical activity score (CAS), severity of eye changes (NOSPECS) status, and to the concentrations of TRAbs or the IGF1 receptor (IGF1R-aAB). The authors verified that the Se serum levels and SELENOP were associated, “indicating a suboptimal Se status of GO patients” [69]. The majority of GO patients from this German cohort had a relatively poor Se status ([Se] ± SD; 70.0 ± 23.8 µg/L), below the threshold needed for full expression of selenoproteins. However, the retrospective nature of the study is a limitation to establish conclusions on a potential causative role of Se on GD and/or GO risk [69].

The ongoing GRASS trial (GRAves’s disease Selenium Supplementation trial) that enrolled 492 patients with Graves’ hyperthyroidism can bring, in the future, more information in the issue [70]. The purpose of this study is to investigate selenium supplementation (200 µg/day of selenium-enriched yeast) in complement to the standard treatment with anti-thyroid drugs in patients with Graves’ hyperthyroidism during a long period of time (24 to 30 months). The outputs of the study are response to anti-thyroid drugs treatment, time for remission and duration of the remission, and quality of life during the first year of treatment [70].

2. Conclusions

Selenium supplementation is not yet recommended in international guidelines for treatment of AITD. Using a questionnaire study among Italian Endocrinologists, Negro, reported that selenium supplementation is currently used despite not being recommended in the guidelines. However, regarding Graves’ orbitopathy, the European Thyroid Association recommends a six-month trial period. Selenium supplementation in patients with Hashimoto’s thyroiditis with known selenium deficiency may be useful, even for those who are already being treated with levothyroxine, although further studies are needed to confirm this benefit. In patients with mild to moderate Graves’ orbitopathy, selenium supplementation seems to be beneficial and the organic formula (selenomethionine) seems to be more efficient than the inorganic formula. Additional studies will allow for the stratification of patients that are most likely to benefit from selenium supplementation.

Author Contributions: P.S. and L.R.S. conceived and designed the paper; L.R.S. wrote the first version of the paper; M.M. and C.N. contributed with clinical endocrinological data; P.S. reviewed and L.R.S., M.M. and C.N. contribute to the revision of the final version.

Acknowledgments: The authors thank to João Vinagre the helpful discussion and the help in the paper editing. Funding was obtained from FEDER—Funduo Europeu de Desenvolvimento Regional funds through the COMPETE 2020—Operational Program for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through FCT—Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274), and by the project “Advancing cancer research: from basic acknowledgement to application”; NORTE-01-0145-FEDER-000029; Projetos Estruturados de I & D & I, funded by Norte 2020-Programa Operacional Regional do Norte. Miguel Melo received a grant from Genzyme for the research project “Molecular biomarkers of prognosis and response to therapy in differentiated thyroid carcinomas”.

Conflicts of Interest: The authors declare no conflict of interest.
Diagnostics 2018, 8, 70

23. Carlson, B.A.; Lee, B.J.; Tsuji, P.A.; Copeland, P.R.; Schweizer, U.; Gladyshev, V.N.; Hatfield, D.L. Selenocysteine tRNA[Ser][Sec], the central component of selenoprotein biosynthesis: Isolation, identification, modification, and sequencing. Methods Mol. Biol. 2018, 1661, 43–60. [PubMed]

24. Goyens, P.; Golstein, J.; Naombola, B.; Vis, H.; Dumont, J.E. Selenium deficiency as a possible factor in the pathogenesis of myxoedematous endemic cretinism. Acta Endocrinol. 1987, 114, 497–502. [CrossRef] [PubMed]

25. Contempre, B.; Duale, N.L.; Dumont, J.E.; Ngo, B.; Diplock, A.T.; Vanderpas, J. Effect of selenium supplementation on thyroid hormone metabolism in an iodine and selenium deficient population. Clin. Endocrinol. 1992, 36, 579–583. [CrossRef]

26. Rotruck, J.T.; Pope, A.L.; Ganther, H.E.; Swanson, A.B.; Hafeman, D.G.; Hoekstra, W.G. Selenium: Biochemical role as a component of glutathione peroxidase. Science 1973, 179, 588–590. [CrossRef] [PubMed]

27. Schomburg, L. Selenium, selenoproteins and the thyroid gland: Interactions in health and disease. Nat. Rev. Endocrinol. 2011, 8, 160–171. [CrossRef] [PubMed]

28. Bermano, G.; Nicol, F.; Dyer, J.A.; Sunde, R.A.; Beckett, G.J.; Arthur, J.R.; Hesketh, J.E. Tissue-specific regulation of selenocyte gene expression during selenium deficiency in rats. Biochem. J. 1995, 311, 425–430. [CrossRef] [PubMed]

29. Kawai, M.; Shoji, Y.; Onuma, S.; Etani, Y.; Ida, S. Thyroid hormone status in patients with severe selenium deficiency. Clin. Pediatr. Endocrinol. 2018, 27, 67–74. [CrossRef] [PubMed]

30. Schoenmakers, E.; Agostini, M.; Mitchell, C.; Schoenmakers, N.; Papp, L.; Rajanayagam, O.; Padidela, R.; Ceron-Gutierrez, L.; Doffinger, R.; Prevosto, C.; et al. Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. J. Clin. Investig. 2010, 120, 4221–4235. [CrossRef] [PubMed]

31. Schoenmakers, E.; Chatterjee, K. Identification of genetic disorders causing disruption of selenoprotein biosynthesis. Methods Mol. Biol. 2018, 1661, 325–335. [PubMed]

32. Dumitrescu, A.M.; Liao, X.H.; Abdullah, M.S.; Lado-Abeal, J.; Majed, F.A.; Moeller, L.C.; Boran, G.; Schomburg, L.; Weiss, R.E.; Refetoff, S. Mutations in SECSBP2 result in abnormal thyroid hormone metabolism. Nat. Genet. 2005, 37, 1247–1252. [CrossRef] [PubMed]

33. Di Cosmo, C.; McLellan, N.; Liao, X.H.; Khanna, K.K.; Weiss, R.E.; Papp, L.; Refetoff, S. Clinical and molecular characterization of a novel selenocysteine insertion sequence-binding protein 2 (SBP2) gene mutation (R128X). J. Clin. Endocrinol. Metab. 2009, 94, 4003–4009. [CrossRef] [PubMed]

34. Catli, G.; Fujisawa, H.; Kirbiyik, O.; Mimoto, M.S.; Gencpinar, P.; Ozdemir, T.R.; Dundar, B.N.; Dumitrescu, A.M. A novel homozygous selenocysteine insertion sequence binding protein 2 (SECSBP2, SBP2) gene mutation in a turkish boy. Thyroid 2018, 28, 1221–1223. [CrossRef] [PubMed]

35. Weetman, A.P. Autoimmune thyroid disease. Autoimmunity 2004, 37, 337–340. [CrossRef] [PubMed]

36. Ban, Y.; Tomer, Y. Genetic susceptibility in thyroid autoimmunity. Pediatr. Endocrinol. Rev. 2005, 3, 20–32. [PubMed]

37. Hwangbo, Y.; Park, Y.J. Genome-wide association studies of autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J. Clin. Endocrinol. Metab. 2002, 87, 1687–1691. [CrossRef] [PubMed]
44. Karanikas, G.; Schuetz, M.; Kontur, S.; Duan, H.; Komnata, S.; Schoen, R.; Antoni, A.; Kletter, K.; Dudczak, R.; Willheim, M. No immunological benefit of selenium in consecutive patients with autoimmune thyroiditis. *Thyroid* **2008**, *18*, 7–12. [CrossRef] [PubMed]

45. Kachouei, A.; Rezvanian, H.; Amini, M.; Aminrooaya, A.; Moradi, E. The effect of levothyroxine and selenium versus levothyroxine alone on reducing the level of anti-thyroid peroxidase antibody in autoimmune hypothyroid patients. *Adv. Biomed. Res.* **2018**, *7*, 1. [PubMed]

46. Eskes, S.A.; Endert, E.; Fliers, E.; Birnie, E.; Hollenbach, B.; Schomburg, L.; Kahrle, J.; Wiersinga, W.M. Selenite supplementation in euthyroid subjects with thyroid peroxidase antibodies. *Clin. Endocrinol.* **2014**, *80*, 444–451. [CrossRef] [PubMed]

47. Turker, O.; Kumanlioglu, K.; Karapalot, I.; Dogan, I. Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. *J. Endocrinol.* **2006**, *190*, 151–156. [CrossRef] [PubMed]

48. Anastasilakis, A.D.; Toulis, K.A.; Nisianakis, P.; Goulis, D.G.; Kampas, L.; Valeri, R.M.; Oikonomou, D.; Tzellos, T.G.; Delaroudis, S. Selenomethionine treatment in patients with autoimmune thyroiditis: A prospective, quasi-randomised trial. *Int. J. Clin. Pract.* **2012**, *66*, 378–383. [CrossRef] [PubMed]

49. De Farias, C.R.; Cardoso, B.R.; de Oliveira, G.M.; de Mello Guazzelli, I.C.; Catarino, R.M.; Chammam, M.C.; Cozzolino, S.M.; Knobel, M. A randomized-controlled, double-blind study of the impact of selenium supplementation on thyroid autoimmunity and inflammation with focus on the gpx1 genotypes. *J. Endocrinol. Invest.* **2015**, *38*, 1065–1074. [CrossRef] [PubMed]

50. Duntas, L.H.; Mantzou, E.; Koutaras, D.A. Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. *Eur. J. Endocrinol.* **2003**, *148*, 389–393. [CrossRef] [PubMed]

51. Mazokopakis, E.E.; Papadakis, J.A.; Papadomanolaki, M.G.; Batistakis, A.G.; Giannakopoulos, T.G.; Protopopadakis, E.E.; Ganotakis, E.S. Effects of 12 months treatment with l-selenomethionine on serum anti-tpo levels in patients with hashimoto’s thyroiditis. *Thyroid* **2007**, *17*, 609–612. [CrossRef] [PubMed]

52. Esposito, D.; Rotondi, M.; Accardo, G.; Vallone, G.; Conzo, G.; Docimo, G.; Selvaggi, F.; Cappelli, C.; Chiocciolo, L.; Giugliano, D.; et al. Influence of short-term selenium supplementation on the natural course of hashimoto’s thyroiditis: Clinical results of a blinded placebo-controlled randomized prospective trial. *J. Endocrinol. Invest.* **2017**, *40*, 83–89. [CrossRef] [PubMed]

53. Nacamulli, D.; Mian, C.; Petrica, D.; Lazzarotto, F.; Barollo, S.; Pozza, D.; Masiero, S.; Faggian, D.; Plebani, M.; Girelli, M.E.; et al. Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis. *Clin. Endocrinol.* **2010**, *73*, 535–539. [CrossRef] [PubMed]

54. Pilli, T.; Cantara, S.; Schomburg, L.; Cenci, V.; Cardinale, S.; Heid, E.C.; Kuhn, E.C.; Cevenini, G.; Sestini, F.; Fioravanti, C.; et al. Ifngamma-inducible chemokines decrease upon selenomethionine supplementation in women with euthyroid autoimmune thyroiditis: Comparison between two doses of selenomethionine (80 mug or 160 mug) versus placebo. *Eur. Thyroid J.* **2015**, *4*, 226–233. [CrossRef] [PubMed]

55. Kvicala, J.; Hrdla, P.; Zamrazil, V.; Nemecek, J.; Hill, M.; Jiraneck, V. Effect of selenium supplementation on thyroid antibodies. *J. Radiat. Nucl. Chem.* **2009**, *280*, 275–279. [CrossRef] [PubMed]

56. Gartner, R.; Gasnier, B.C. Selenium in the treatment of autoimmune thyroiditis. *Biofactors* **2003**, *19*, 165–170. [CrossRef] [PubMed]

57. Ferrari, S.M.; Fallahi, P.; Di Bari, F.; Vita, R.; Benvenga, S.; Antonelli, A. Myo-inositol and selenium reduce the risk of developing overt hypothyroidism in patients with autoimmune thyroiditis. *Eur. Rev. Med. Pharmacol. Sci.* **2017**, *21*, 36–42. [PubMed]

58. Van Zauren, E.J.; Albusta, A.Y.; Fedorowicz, Z.; Carter, B.; Pijl, H. Selenium supplementation for hashimoto’s thyroiditis: Summary of a cochrane systematic review. *Eur. Thyroid J.* **2014**, *3*, 25–31. [CrossRef] [PubMed]

59. Wichman, J.; Winther, K.H.; Bonnema, S.J.; Hegedus, L. Selenium supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis: A systematic review and meta-analysis. *Thyroid* **2016**, *26*, 1681–1692. [CrossRef] [PubMed]

60. Winther, K.H.; Watt, T.; Bjorner, J.B.; Cramon, P.; Feldt-Rasmussen, U.; Gluud, C.; Gram, J.; Groenvold, M.; Hegedus, L.; Knudsen, N.; et al. The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): Study protocol for a randomized controlled trial. *Trials* **2014**, *15*, 115. [CrossRef] [PubMed]

61. Al-Kunani, A.S.; Knight, R.; Haswell, S.J.; Thompson, J.W.; Lindow, S.W. The selenium status of women with a history of recurrent miscarriage. *BJOG* **2001**, *108*, 1094–1097. [PubMed]
62. Negro, R.; Greco, G.; Mangieri, T.; Pezzarossa, A.; Dazzi, D.; Hassan, H. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J. Clin. Endocrinol. Metab. 2007, 92, 1263–1268. [CrossRef] [PubMed]

63. Vrca, V.B.; Skreb, F.; Cepelak, I.; Romic, Z.; Mayer, L. Supplementation with antioxidants in the treatment of Graves’ disease; the effect on glutathione peroxidase activity and concentration of selenium. Clin. Chim. Acta 2004, 341, 55–63. [CrossRef] [PubMed]

64. Wang, L.; Wang, B.; Chen, S.R.; Hou, X.; Wang, X.F.; Zhao, S.H.; Song, J.Q.; Wang, Y.G. Effect of selenium supplementation on recurrent hyperthyroidism caused by Graves’ disease: A prospective pilot study. Horm. Metab. Res. 2016, 48, 559–564. [CrossRef] [PubMed]

65. Wertenbruch, T.; Willenberg, H.S.; Sagert, C.; Nguyen, T.B.; Bahlo, M.; Feldkamp, J.; Groeger, C.; Hermansen, D.; Scherbaum, W.A.; Schott, M. Serum selenium levels in patients with remission and relapse of Graves’ disease. Med. Chem. 2007, 3, 281–284. [CrossRef] [PubMed]

66. Leo, M.; Bartalena, L.; Rotondo Dottore, G.; Piantanida, E.; Premoli, P.; Ionni, I.; Di Cera, M.; Masiello, E.; Sassi, L.; Tanda, M.L.; et al. Effects of selenium on short-term control of hyperthyroidism due to Graves’ disease treated with methimazole: Results of a randomized clinical trial. J. Endocrinol. Invest. 2017, 40, 281–287. [CrossRef] [PubMed]

67. Marcocci, C.; Kahaly, G.J.; Krassas, G.E.; Bartalena, L.; Prummel, M.; Stahl, M.; Altea, M.A.; Nardi, M.; Pitz, S.; Boboridis, K.; et al. Selenium and the course of mild Graves’ orbitopathy. N. Engl. J. Med. 2011, 364, 1920–1931. [CrossRef] [PubMed]

68. Bartalena, L.; Baldeschi, L.; Boboridis, K.; Eckstein, A.; Kahaly, G.J.; Marcocci, C.; Perros, P.; Salvi, M.; Wiersinga, W.M.; European Group on Graves’ Orbitopathy. The 2016 European thyroid association/european group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur. Thyroid J. 2016, 5, 9–26. [CrossRef] [PubMed]

69. Dehina, N.; Hofmann, P.J.; Behrends, T.; Eckstein, A.; Schomburg, L. Lack of association between selenium status and disease severity and activity in patients with Graves’ ophthalmopathy. Eur. Thyroid J. 2016, 5, 57–64. [CrossRef] [PubMed]

70. Watt, T.; Cramon, P.; Bjorner, J.B.; Bonnema, S.J.; Feldt-Rasmussen, U.; Gluud, C.; Gram, J.; Hansen, J.L.; Hegeduš, L.; Knudsen, N.; et al. Selenium supplementation for patients with Graves’ hyperthyroidism (the grass trial): Study protocol for a randomized controlled trial. Trials 2013, 14, 119. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).